Drug Profile
Darbepoetin alfa biosimilar - AvesthaGen
Alternative Names: Avdesp™Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Avesthagen
- Developer Avesthagen; IQVIA
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 01 Mar 2016 No recent reports on development identified - Phase-III for Anaemia in India (Parenteral)
- 17 Jun 2011 Darbepoetin alfa biosimilar - AvesthaGen is available for global licensing as of 17 Jun 2011. http://www.avesthagen.com/
- 17 Jun 2011 Phase-III clinical trials in Anaemia in India (Parenteral)